Sage Healthcare and Roth Capital Partners have announced a strategic collaboration to identify and assess ex-US healthcare and life-science companies that may benefit from Sage's transaction advisory experience and Roth's US capital markets expertise.
The collaboration may be relevant to companies approaching clinical, regulatory or commercial milestones, seeking public or private equity financing, or considering licensing, partnering, M&A and financing alternatives in parallel.
The collaboration brings together Sage's specialist capabilities in licensing, partnering and M&A, its European healthcare network and Roth's healthcare investment banking, financing strategy and US capital markets services.
It is designed for selected companies where strategic transaction planning and financing needs are closely connected - for example, businesses approaching clinical, regulatory or commercial milestones, evaluating partnering or M&A alternatives, or seeking equity capital to support development and growth.
Sage can support transaction readiness, strategic positioning, partner and buyer identification, market engagement and execution. Roth may, subject to its independent assessment, approvals, regulatory requirements and a separate engagement where appropriate, evaluate relevant companies for financing, institutional investor access and other investment-banking or capital-markets services.
If your company is considering licensing, partnering, M&A, public or private equity financing - or wishes to assess several alternatives in parallel - we would welcome an initial confidential discussion.
To discuss whether this may be relevant to your company, please contact Dr Bill Mason at wtm@sagehealthcare.com.
